Echocardiographic predictors of symptomatic cardiotoxicity among patients undergoing chemotherapy: A systematic review and meta-analysis.
Muhammad Umer SiddiquiYoussef YaacoubHeidi-Anne HansonJoey JunartaAhmed K PashaMahek ShahPublished in: Medicine (2022)
GLS may predict symptomatic cardiotoxicity and be used to monitor patients on chemotherapy for symptomatic cardiac dysfunction. While the pooled results for baseline LVEF identified that it is not a predictor of symptomatic cardiotoxicity, this differs from the findings of the only randomized trial included in this meta-analysis. The data for baseline GLS as a predictor of symptomatic cardiotoxicity is encouraging, but definite evidence that GLS may be superior to LVEF is lacking. Prospective randomized, blinded trials are required to identify if 1 echocardiographic parameter may be superior to the other.
Keyphrases
- ejection fraction
- left ventricular
- systematic review
- patients undergoing
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- locally advanced
- squamous cell carcinoma
- randomized controlled trial
- placebo controlled
- open label
- left atrial
- prognostic factors
- phase iii
- clinical trial
- radiation therapy
- patient reported outcomes
- big data
- atrial fibrillation
- patient reported
- artificial intelligence